Stem cell transplantation for immunoglobulin light chain amyloidosis

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Systemic chemotherapy aimed at eradicating transformed plasma cells is the mainstay of treatment for immunoglobulin light chain amyloidosis (AL). Autologous stem cell transplantation (SCT) is a highly effective treatment for AL and can lead to long term survival in excess of 10 years in patients who achieve complete remission. Since AL is a unique disease characterized by multiple organ dysfunction, SCT poses unique challenges in this disease. Morbidity and mortality of SCT has remarkably improved over time primarily due to careful selection of patients and evolution of predictive and prognostic models based on serum immunoglobulin light chains and cardiac biomarkers. In this review we focus on the historical evolution of SCT as a treatment for AL and unique challenges it poses in the management of this rare disease and provide guidelines for managing these challenges.

Original languageEnglish (US)
Pages (from-to)129-137
Number of pages9
JournalCurrent Problems in Cancer
Volume41
Issue number2
DOIs
StatePublished - Mar 1 2017

Fingerprint

Immunoglobulin Light Chains
Stem Cell Transplantation
Amyloidosis
Rare Diseases
Plasma Cells
Patient Selection
Therapeutics
Biomarkers
Guidelines
Morbidity
Drug Therapy
Survival
Mortality
Serum

Keywords

  • AL
  • Immunoglobulin light chain amyloidosis
  • Stem cell transplantation
  • Stem cell transplantation for AL

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Stem cell transplantation for immunoglobulin light chain amyloidosis. / Sher, Taimur; Gertz, Morie.

In: Current Problems in Cancer, Vol. 41, No. 2, 01.03.2017, p. 129-137.

Research output: Contribution to journalReview article

@article{42fff31537c44f2db349c4a0ee2c9a94,
title = "Stem cell transplantation for immunoglobulin light chain amyloidosis",
abstract = "Systemic chemotherapy aimed at eradicating transformed plasma cells is the mainstay of treatment for immunoglobulin light chain amyloidosis (AL). Autologous stem cell transplantation (SCT) is a highly effective treatment for AL and can lead to long term survival in excess of 10 years in patients who achieve complete remission. Since AL is a unique disease characterized by multiple organ dysfunction, SCT poses unique challenges in this disease. Morbidity and mortality of SCT has remarkably improved over time primarily due to careful selection of patients and evolution of predictive and prognostic models based on serum immunoglobulin light chains and cardiac biomarkers. In this review we focus on the historical evolution of SCT as a treatment for AL and unique challenges it poses in the management of this rare disease and provide guidelines for managing these challenges.",
keywords = "AL, Immunoglobulin light chain amyloidosis, Stem cell transplantation, Stem cell transplantation for AL",
author = "Taimur Sher and Morie Gertz",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.currproblcancer.2017.03.001",
language = "English (US)",
volume = "41",
pages = "129--137",
journal = "Current Problems in Cancer",
issn = "0147-0272",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Stem cell transplantation for immunoglobulin light chain amyloidosis

AU - Sher, Taimur

AU - Gertz, Morie

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Systemic chemotherapy aimed at eradicating transformed plasma cells is the mainstay of treatment for immunoglobulin light chain amyloidosis (AL). Autologous stem cell transplantation (SCT) is a highly effective treatment for AL and can lead to long term survival in excess of 10 years in patients who achieve complete remission. Since AL is a unique disease characterized by multiple organ dysfunction, SCT poses unique challenges in this disease. Morbidity and mortality of SCT has remarkably improved over time primarily due to careful selection of patients and evolution of predictive and prognostic models based on serum immunoglobulin light chains and cardiac biomarkers. In this review we focus on the historical evolution of SCT as a treatment for AL and unique challenges it poses in the management of this rare disease and provide guidelines for managing these challenges.

AB - Systemic chemotherapy aimed at eradicating transformed plasma cells is the mainstay of treatment for immunoglobulin light chain amyloidosis (AL). Autologous stem cell transplantation (SCT) is a highly effective treatment for AL and can lead to long term survival in excess of 10 years in patients who achieve complete remission. Since AL is a unique disease characterized by multiple organ dysfunction, SCT poses unique challenges in this disease. Morbidity and mortality of SCT has remarkably improved over time primarily due to careful selection of patients and evolution of predictive and prognostic models based on serum immunoglobulin light chains and cardiac biomarkers. In this review we focus on the historical evolution of SCT as a treatment for AL and unique challenges it poses in the management of this rare disease and provide guidelines for managing these challenges.

KW - AL

KW - Immunoglobulin light chain amyloidosis

KW - Stem cell transplantation

KW - Stem cell transplantation for AL

UR - http://www.scopus.com/inward/record.url?scp=85018169587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018169587&partnerID=8YFLogxK

U2 - 10.1016/j.currproblcancer.2017.03.001

DO - 10.1016/j.currproblcancer.2017.03.001

M3 - Review article

C2 - 28457657

AN - SCOPUS:85018169587

VL - 41

SP - 129

EP - 137

JO - Current Problems in Cancer

JF - Current Problems in Cancer

SN - 0147-0272

IS - 2

ER -